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A proportion of patients diagnosed with melanoma has a 
positive family history. Despite increasing knowledge on 
the genes responsible for familial clustering, the genetic 
basis in the majority of the families with an inherited 
predisposition to melanoma remains to be clarified. To 
identify novel melanoma-susceptibility genes, we applied 
whole-exome sequencing on DNA from two members 
of a family with four melanoma cases, not explained by 
established high penetrance melanoma-susceptibility 
genes. Whole-exome sequencing identified 10 rare, 
co-segregating, predicted deleterious missense gene 
variants. Subsequent co-segregation analysis revealed 
that only variants in the DOT1L (R409H) and the SLCO4C1 
(P597A) genes were present in the other two affected 
members of this family. DOT1L is a methyltransferase that 
methylates histone H3 lysine 79 (H3K79). It is involved 
in maintenance of genomic stability, since mutations 
in the DOT1L gene have been previously reported to 
compromise the removal of ultraviolet photoproducts 
in ultraviolet-irradiated melanocytes, thereby enhancing 
malignant transformation. We hypothesized that the 
presence of DOT1L R409H variant might be associated 
with an increased risk of melanoma, since we found 
co-segregation of the DOT1L mutation in all four 
melanoma-affected family members. However, this 
missense variant did neither lead to detectable loss- 
of-heterozygosity nor reduction of histone 
methyltransferase activity in melanoma samples from 
mutation carriers nor altered ultraviolet-survival of 
mouse embryonic stem cells containing an engineered 
homozygous DOT1L R409H mutation. Although functional 
analysis of this rare co-segregating variant did not reveal 
compromised histone methyltransferase activity and 
ultraviolet exposure sensitivity, the role of DOT1L as 
melanoma susceptibility gene deserves further study. 
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Introduction
Cutaneous melanoma is an aggressive form of skin can-
cer and the leading cause of death among all skin cancer 
patients [1]. Approximately 10% of melanoma cases pres-
ent familial clustering. In Europe, familial melanoma is 
defined as the occurrence of three or more melanomas in 
multiple members of a family, at least two of which are 
diagnosed in first-degree relatives. Thus far only in ~50% 
of melanoma families, the melanoma susceptibility can 
be attributed to a genetic defect in the high and medium 
penetrance melanoma genes such as CDKN2A, CDK4, 
BAP1, TERT, POT1, ACD, MITF and TERF2IP [2]. 
Clarifying the genetic basis of melanoma predisposition 
is of major clinical importance since new genetic test-
ing can be approved and more personalized surveillance 
offered to the patients [3]. Exome-wide sequencing 
approaches can be valuable in the identification of puta-
tive new-melanoma susceptibility genes [4].
In the present study, we describe a Dutch family of 
which four family members were diagnosed with mel-
anoma. Whole-exome sequencing (WES) of DNA from 
two family members identified a new germline missense 
variant c.G1226A:p.R409H in the DOT1L gene, that 
co-segregated with melanoma in all four affected family 
members. DOT1L is the unique histone methyltrans-
ferase responsible for methylating the nucleosome core 
on lysine 79 of histone H3 (H3K79) [5,6]. The observed 
DOT1L variant appeared to be the most promising patho-
genic variant since recently loss of DOT1L (by silencing or 
mutation) has been reported to promote melanomagene-
sis in a pre-clinical mouse model upon ultraviolet (UV) 
radiation [7]. The role of DOT1L in DNA damage repair 
pathway involves the transcriptional recovery through 
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reactivation of RNA Pol II in mouse-derived cell lines 
[8] and the recruitment of XPC for an efficient nucleotide 
excision repair in melanocytes and cell lines derived from 
human melanoma, thereby protecting melanocytes from 
the UV-induced transition to melanoma [7].
We hypothesized that in the family under study, the 
R409H DOT1L variant represents a loss of function muta-




DNA from members of a Dutch family with four family 
members affected with melanoma was isolated from whole 
blood samples, a primary tumor and a brain metastasis. The 
study was approved by the Leiden University Medical 
Center institutional ethical committee (LUMC, P00.117). 
The affected family members were tested negative for var-
iants in the high penetrance genes CDKN2A and CDK4 and 
cases II.2 and III.3 were subjected to WES (Fig. 1).
Whole-exome sequencing
Whole-exome sequencing was performed using Agilent 
All-exon capture baits (Agilent Technologies, Santa 
Clara, California, USA) and sequenced on the Illumina 
platform at Sanger Institute, Cambridge, UK. The bio-
informatics analysis and subsequent filtering steps were 
performed at Sanger Institute and later confirmed by our 
in-house bioinformatics pipeline. Briefly, the reads were 
aligned to the human genome build hg19 using Burrows-
Wheeler Alignment tool [9]. To pass the filtering steps 
the variants needed to have a high-quality score (>30), 
to have high coverage (>40×), to be a nonsynonymous 
single nucleotide variant, to be heterozygous present in 
both samples, to have low ExAC frequency (<0.001), and 
needed to be predicted as deleterious and damaging by 
Polyphen and SIFT. Variants which did not fulfill all the 
filtering criteria were excluded, resulting in a list of 10 
variants of interest (Table 1).
Co-segregation analysis
All 10 variants were confirmed by Sanger sequencing using 
DNA from the two family members subjected to WES (II.2 
and III.3, see Figure, Supplemental Digital Content 1, 
http://links.lww.com/MR/A177). Briefly, 20–100 ng of DNA 
was amplified through a touchdown PCR using the 
Platinum Taq DNA Polymerase following the manu-
facturer’s instructions (Invitrogen, Carlsbad,  California, 
USA). The PCR product was cleaned-up using the 
NucleoSpin Gel and PCR Clean-Up (Macherey-Nagel 
GmbH & Co. KG, Düren, Germany) according to manu-
facturer’s instructions. Then, Sanger sequencing was per-
formed using 20–50 ng of purified DNA mixed with 1 μl 
of 10 μM of sequencing primer and nuclease-free water 
(B. Braun, Melsungen, Germany) up to 10 μl. Later on, 
we used the same approach to evaluate the co-segrega-
tion of these variants with melanoma in all affected family 
members (see Figure, Supplemental Digital Content 2, 
http://links.lww.com/MR/A178 and Fig. 2)
Loss of heterozygosity analysis
Loss of heterozygosity (LOH) was assessed by droplet 
digital PCR (ddPCR). Tumors from two family mem-
bers were examined: a formalin-fixed paraffin-embedded 
(FFPE)-derived primary melanoma biopsy from II.1 and 
a brain metastasis from III.2 (Fig. 2). The DNA extrac-
tion was performed using Tissue Preparation System 
(Siemens Healthcare GmbH, Erlangen, Germany) at 
the Department of Pathology, LUMC. Briefly, 10 ng of 
DNA was combined with 1X ddPCR Mut Assay DOT1L 
R409H (dHsaMDS130625855; Bio-Rad Laboratories, 
Inc., Hercules, California, USA), 1X ddPCR supermix 
for probes (no dUTP) (Bio-Rad), 1 U/μl MseI restriction 
enzyme [New England Biolabs, Inc. (NEB), Ipswich, 
Fig. 1
Family pedigree. The melanoma affected members are in dark gray 
color (II.1, II.2, III.2, III.3). The age of diagnosis is indicated in brackets. 
The melanoma cases subjected to whole-exome sequencing are 
indicated by an ‘WES’.
Table 1 Germline variants identified by whole exome sequenc-
ing shared by two affected family members of a four case Dutch 
melanoma family
Gene Location Variant Amino acid substitution
SLCO4C1 Chr5: 101582978-101582978 G > C P597A
PEX6 Chr6: 42932102-42932102 G > A R972C; R884C
FBXL13 Chr7: 102462622-102462622 G > A S583L; S600L; S628L
NAIF1 Chr9: 130825802-130825802 G > A R297C
LAMC3 Chr9: 133914340-133914340 C > T R356C
CIT Chr12: 120152035-120152035 C > T V1383M; V1425M
FREM2 Chr13: 39433637-39433637 C > T R2477W
DOT1L Chr19: 2210729-2210729 G > A R409H
FUT1 Chr19: 49253896-49253896 C > A V215F
UMODL1 Chr21: 43508479-43508479 G > A V155M; V227M
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Massachusetts, USA] diluted in its own buffer CutSmart 
(NEB) and nuclease-free water (B. Braun) up to 22  μl. 
To generate droplets the Automated Droplet Generator 
(Bio-Rad Laboratories, Inc.) was used, followed by the 
PCR using the cycling conditions for Bio-Rad’s C1000 
Touch Thermal Cycler (Bio-Rad Laboratories, Inc.) with 
an annealing temperature of 55 °C. The number of drop-
lets was determined by the QX200 Droplet Reader (Bio-
Rad Laboratories, Inc.) and analysed using QuantaSoft 
version 1.7.4.0917 (Bio-Rad Laboratories, Inc.).
Immunohistochemistry
For immunohistochemistry (IHC, see Figure, 
Supplemental Digital Content 3, http://links.lww.com/MR/
A179), sections from FFPE-derived primary melanomas 
from II.1 and brain metastasis from III.2, along with EAF 
(ethanol, acetic acid, formol saline) fixed and paraffin-em-
bedded thymus tissues from mice with conditional dele-
tion of Dot1L [10] were pre-incubated with goat serum 
(Dako; Agilent Technologies) for 30 minutes and then 
incubated overnight with H3K79me2 antibody (1:8000 
dilution, RRID:AB_1587126 [11]) followed by incuba-
tion with Dako EnVision+ System HRP labeled poly-
mer anti-rabbit (Agilent Technologies) for 30 minutes. 
The slides were washed with PBS, incubated with Dako 
3,3′-diaminobenzidine substrate chromogen system 
(dilution 1:50; Agilent Technologies), and counterstained 
with hematoxylin (Merck KGaA, Darmstadt, Germany).
Cell lines generation
IB10 wild-type mouse embryonic stem cells (mESCs) 
were used to engineer site-specific mutations using 
CRISPR/Cas9 to generate mESC lines expressing 
DOT1L R409H or the catalytic site mutant DOT1L G165R 
according to the protocol described by Harmsen et al. [12]. 
IB10 mESCs were cultured on a feeder layer of irradiated 
murine embryonic fibroblasts in complete medium con-
taining GMEM-BHK12 (Gibco/Thermo Fisher Scientific, 
Waltham, Massachusetts, USA), 100 mM Sodium Pyrovate 
(Gibco), non-essential amino acids (Gibco) and 10% ES 
cell certified serum (HyClone/Thermo Fisher Scientific). 
This was complemented with 0.1  μM β-mercaptoetha-
nol (Sigma-Aldrich, St. Louis, Missouri, USA) and mouse 
recombinant leukemia inhibitor factor (Merck KGaA). 
For transfection, cells were grown on gelatin-coated plates 
in 60% Buffalo Rat Liver (BRL) medium (150 ml BRL-
conditioned medium + 100 ml complete medium). Cells 
were incubated at 5% CO
2
, at 37°C.
Oligonucleotides encoding the gRNAs are in 
Supplemental Digital Content 4, http://links.lww.com/MR/
A180. Single strand homology-directed repair (HDR) 
templates are in Supplemental Digital Content 5, http://
links.lww.com/MR/A181. The repair templates were pur-
chased from Sigma-Aldrich, all other oligonucleotides 
from IDT (Leuven, Belgium). The gRNAs were cloned 
into the px330.pgkpuro vector (a gift from Hein te Riele). 
A mixture of 0.1 μg CRISPR/Cas9 vector and 0.4 μg HDR 
template in optiMEM (Gibco) with 1.25  μl TransIT 
LT1 (Mirus Bio LLC, Madison,  Wisconsin, USA) was 
incubated for 15–20 minutes at room temperature and 
added to the cells. The next day cells were replated in 
60% BRL medium containing 3.6 μg/ml puromycin. Two 
days later the medium was replaced with medium with-
out puromycin. Cells were then sparsely seeded to grow 
single clones. After 1 week, single clones were selected 
and genomic DNA was isolated to validate the mutations, 
which also introduced restriction sites. The regions con-
taining the R409H and G165R mutations were amplified 
using MyTaq Redmix (GC-Biotech B.V., Alphen aan 
den Rijn, The Netherlands) and the following prim-
ers: R409H–5′TGCCTCAGCCTATGGTCTTGT and 
5′TGGCACATGGCAGAGTCCCATA, for G165R– 
5′ACTACACAGCCCATGAAGCTGA and 5′TGGTTA 
AGCAGCCACAACCCA. The PCR product contain-
ing the R409H region was digested with MIcI (Thermo 
Fig. 2
Droplet digital PCR results showing the DOT1L mutation fraction in DNA samples extracted from whole blood samples [II.2, III.3 (both subjected 
to WES) and IV.1 and IV.2], a primary melanoma (II.1 FS) and a brain metastasis (III.2 FS). The mutation fraction is around 50% in mutation-
carriers and around 0% in wild-type family members (II.5, II.6, III.4, III.5), as control samples. In a full section (III.2 FS) of the brain metastasis, 
a mutation fraction of ~20% was found. The primary melanoma (II.1 FS) is mutated for DOT1L; however, no LOH was observed. LOH, loss of 
heterozygosity; WES, whole-exome sequencing.
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Fisher Scientific) directly after amplification. PCR prod-
ucts containing the G165R region were purified using 
the QIAquick PCR purification kit (Qiagen, Hilden, 
Germany) according to the manufacturers protocol and 
then digested with BauI (Thermo Fisher Scientific). 
Clones that showed the expected digestion pattern 
were further validated using Sanger sequencing. For 
UV-survival assays three clones with the R409H muta-
tion were selected and two clones that had the G165R 
mutation, of which one had a homozygous G165R and 
one clone with a heterozygous G165R mutation and one 
nucleotide deletion causing a frame-shift in DOT1L.
Ultraviolet-survival assay
To assess UV sensitivity, we performed a colony for-
mation assay upon UV-C exposure in wild-type and 
CRISPR/Cas9 engineered DOT1L mutant mESCs. For 
UV-survival assays mESCs were cultured in 60% BRL 
conditioned medium. One thousand cells were plated 
in a 10-cm dish and grown overnight. The next day 
cells were washed with PBS and exposed to UV-C irra-
diation (254  nm, UV-C irradiation chamber; Dr Gröbel 
UV-Elektronik, GmgH, Germany; dose range: 0.5, 1, 2, 4, 
8 J/m2). After 8 days of incubation the colonies were fixed 
and stained using Leishman’s eosin methylene blue solu-
tion modified (Merck KGaA). Colonies were counted 
with the ColCount (Oxford Optronix Ltd., Abingdon, 
UK).
Western blot
Murine ESCs were grown in feeder-free conditions 
in serum-free ES cell medium containing neuroba-
sal medium (Thermo Fisher Scientific), DMEM/F12 
(Thermo Fisher Scientific), N2 supplement (Thermo 
Fisher Scientific), B27 (Thermo Fisher Scientific) and 
BSA (Thermo Fisher Scientific) supplemented with 
GSK inhibitor CHIR99021 (BioConnect B.V., Huissen, 
The Netherlands) and MEK1&2 inhibitor PD0325901 
(BioConnect) and cell pellets were frozen. Lysates were 
made using 1X SDS sample buffer (50  mM Tris-HCl 
pH 6.8, 2% SDS, 10% glycerol) and sonicated. Samples 
were boiled for 5 minutes in 5X SDS-sample buffer 
(250 mM Tris-HCl pH 6.8, 10% SDS, 50% glycerol, 0.5 
M DTT, 0.5% bromophenol blue) and separated on a 
16% polyacrylamide gel. Separated proteins were trans-
ferred on a 0.45 μm nitrocellulose membrane for 1 hour. 
Membranes were blocked using 2% Nutrilon (Nutricia/
Danone, Schiphol, The Netherlands) in Tris-buffered 
saline containing 0.05% Tween-20 (TBST) for 1 hour 
and incubated overnight with anti-H3K79me1 (RRID: 
AB_2631105), anti-H3K79me2 (RRID: AB_2631106) or 
anti-H3 (ab1791; Abcam, Cambridge, UK). All antibod-
ies were diluted 1:100 in TBST containing 2% Nutrilon. 
After incubation, the membranes were washed three 
times with TBST and incubated with IRDye 800CW goat 
anti-Rabbit igg (1:10 000, Li-COR (RRID: AB_621843)) 
for 45 minutes in TBST with 2% Nutrilon. Then, the 
membranes were washed three times with TBST and 
once in PBS and scanned using an LI-COR Odyssey IR 
Imager (LI-COR Biosciences, Lincoln, Nebraska, USA). 
Images were analysed using Image studio 2.0 (LI-COR 
Biosciences).
Results
R409H, a novel germline variant of the DOT1L gene 
identified in a four case melanoma family
Upon WES of the DNA from two melanoma cases (II.2 
and III.3, Fig. 1), 4892 heterozygote variants were found. 
The bioinformatics analysis encompassed the alignment 
to genome build hg19 and the above-mentioned filtering 
criteria. Frameshift and truncating variants were found 
but did not pass the ExAC filter. Only 10 rare, co-seg-
regating, predicted deleterious missense variants in 
the genes SLCO4C1, PEX6, FBXL13, NAIF1, LAMC3, 
CIT, FREM2, DOT1L, FUT1, UMODL1 met our criteria 
(Table 1). The presence of these 10 germline variants in 
the two cases (II.2 and III.3) subjected to WES was con-
firmed by Sanger sequencing in DNA derived from blood 
leukocytes (see Figure, Supplemental Digital Content 1, 
http://links.lww.com/MR/A177). Subsequently, co-segrega-
tion of the variants was evaluated in other family mem-
bers for whom DNA was available (II.1, 2, 5, 6; III. 2, 3, 4, 
5; IV. 1, 2; data not shown).
Only two out of 10 variants co-segregated with mela-
noma in all four affected relatives: c.C1789G:p.P597A in 
SLCO4C1 gene and c.G1226A:p.R409H in DOT1L gene 
(see Figure, Supplemental Digital Content 2, http://
links.lww.com/MR/A178 and Fig. 2). The SLCO4C1 gene 
encodes for a member of the organic anion transport-
ing polypeptide family. Human SLCO4C1 is involved 
in the membrane transport of cardiac glycosides, thy-
roid hormones, bile acids and many other compounds 
[13]. However, a putative function for SLCO4C1 in can-
cer development is unclear. Only two studies describe 
SLCO4C1 mutation or silencing in head and neck 
cancers, affecting the platinum uptake and clearance 
[14,15]. SLCO4C1 is not expressed in melanocytes and 
melanomas according to publicly available databases 
[16,17]. Taken together, these reasons appear to exclude 
SLCO4C1 as a candidate susceptibility gene for the fam-
ily under investigation.
DOT1L is the unique histone methyltransferase respon-
sible for methylating the nucleosome core on H3K79. 
Based on the function of the DOT1L gene in UV-induced 
DNA damage repair and its reported role in melanoma 
development, we considered the DOT1L gene variant a 
strong candidate responsible for melanoma susceptibility 
in this family. Additional rare and possibly deleterious var-
iants were found in four sporadic and familial melanoma 
cases from the UK (Table 2). Moreover, the 19p13.3 locus, 
containing DOT1L gene, has been shown to be frequently 
deleted in metastatic melanoma cases [18].
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Absence of loss of heterozygosity and altered 
methyltransferase capacity in tumor samples from 
melanoma-affected family members
First, we assessed LOH of DOT1L p.R409H by Sanger 
sequencing and ddPCR analysis in a FFPE-derived pri-
mary melanoma biopsy from individual II.1 and mel-
anoma brain metastasis from individual III.2. In the 
ddPCR result, the mutation fraction is about 50% in 
mutation-carriers [II.2, III.3 (both subjected to WES) and 
IV.1 and IV.2, the youngest family members who did not 
develop melanoma yet] and close to 0% in wild-type fam-
ily members (II.5, II.6, III.4 and III.5). We observed a low 
mutation fraction in the metastasis from III.2 (~20%) and 
a mutation fraction of about 56% in the primary tumor 
from II.1 (Fig.  2). These numbers show an absence of 
LOH in the primary tumor and the brain metastasis.
Then, we checked whether this variant might be involved 
in a generation of a new splice site. Through Human 
Splicing Finder [19], the splicing motif is not altered due 
to the nucleotide substitution. Therefore, there is no indi-
cation that this variant might have an impact on splicing.
Since three previously reported somatic loss-of-function 
DOT1L mutations in melanoma affect the methyltrans-
ferase activity [7], we aimed to assess whether the DOT1L 
mutation identified in our family disturbs DOT1L pro-
tein function by assessing H3K79 methylation via IHC. 
A positive and negative controls derived from mouse thy-
mus tissue were included to demonstrate the sensitivity 
of H3k79me antibody. A high percentage (~80%) of pos-
itive staining nuclei in primary melanoma from II.1 and 
brain metastasis from III.2 could be observed (see Figure, 
Supplemental Digital Content 3, http://links.lww.com/MR/
A179), indicating that the methyltransferase activity is only 
marginally, if at all, affected in the tumors.
R409H variant does not significantly affect the 
ultraviolet sensitivity
We next determined cell survival upon treatment with 
UV-C radiation through a clonogenic assay with the use 
of wild-type and CRISPR-Cas9-engineered homozygous 
DOT1L p.R409H-mutant mESCs. No significant differ-
ence could be observed in survival after UV-irradiation 
between DOT1L p.R409H-mutant and wild-type mESCs 
while DOT1L p.G165R mutant mESCs, expressing a cat-
alytically inactive DOT1L protein showed reduced sur-
vival (Fig. 3a). In mESCs, DOT1L p.R409H mutation did 
not lead to detectable loss of H3K79 methylation, while 
methylation was completely lost in the G165R mutant 
(Fig. 3b).
Table 2 Additional DOT1L variants found in familial and sporadic melanoma cases from the UK
Location Variant
Amino acid  
substitution Polyphen SIFT
Allele frequency  
(gnomAD) Familial history vs. sporadic
Chr19: 2226478 G > A G1320R Possibly damaging Deleterious 1.918e-5 Melanoma family with 2 cases of 
melanoma and multiple primaries
Chr19: 2191090 A > T Y115F Probably damaging Deleterious 0
Chr19: 2226839 G > C S1440T Benign Deleterious 0 Sporadic case, with early onset
Chr19: 2213960 C > T A591V Benign Tolerated 0 Melanoma family with 3 cases of 
melanoma and multiple primaries
Chr19: 2217838 T > C L871P Probably damaging Tolerated 0 Sporadic case, with early onset
Fig. 3
UV-survival assay of WT and DOT1L-mutant mouse embryonic stem cells (mESCs). (a) Colony formation capacity upon UV-C irradiation (dose 
range: 0.5, 1, 2, 4, 8 J/m2) in wild-type, DOT1L-R409H and DOT1L-G165R mutated mESCs (n = 3 independent replicates, error bars represent 
s.d.) (b) Immunoblot analysis of H3K79me levels in the ESC clones used for UV-survival assay. Each lane shows one independently generated 
clone as described in materials and methods. UV, ultraviolet.
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Discussion
Here, we report a novel missense germline mutation in 
the DOT1L gene shared by four first-degree family mem-
bers diagnosed with melanoma with an early age of onset. 
Another variant in SLCO4C1 gene was found to co-seg-
regate with melanoma in the family. However, the lack 
of evidence in association with cancer or expression in 
melanocytes did not encourage us to explore it further. 
On the other hand, DOT1L is a highly evolutionary con-
served protein and is the unique histone methyltrans-
ferase responsible for mono-, di- and trimethylating the 
core of histone H3 on lysine 79 (H3K79) [5,6,20]. In addi-
tion, DOT1L regulates transcription elongation, estab-
lishes cell cycle checkpoints, and maintains genomic 
stability [21,22]. Dysregulation of DOT1L has been asso-
ciated with a number of cancers either as an oncogene or 
tumor suppressor gene [20].
The DOT1L protein has been reported to interact with 
mixed-lineage leukemia (MLL) fusion partners, such 
as AF4, AF9, AF10 and ENL, leading to H3K79 hyper-
methylation and transcriptional activation of target genes 
favoring leukemic transformation [23]. Furthermore, 
DOT1L was described to interact with c-Myc-p300 com-
plex to activate the epithelial-mesenchymal transition 
regulators in breast cancer progression [24]. In addition, 
IL22/STAT3 signaling was reported to increase DOT1L 
expression, which subsequently increased the transcrip-
tion of core stem cell genes, enhancing the cancer stem-
ness and colorectal carcinogenesis, correlating with poor 
patient outcome [25]. In all these studies, DOT1L func-
tions as an oncoprotein.
Recently, DOT1L has been described in colorectal can-
cer as an important player in DNA double-stand break 
repair via homologous recombination through γH2AX 
phosphorylation [26]. Also in melanoma, a role for 
DOT1L in DNA damage repair has been envisioned. 
Three new mutations (M55L, P271L and P505L) in the 
DOT1L gene that negatively affect the catalytic activ-
ity of the methyltransferase were identified [7]. Loss of 
DOT1L (by silencing or mutation) impaired the DNA 
damage repair induced by UV-B radiation, thereby pro-
moting melanoma development in vivo. The authors 
show that DOT1L promotes the assembly of the nucleo-
tide excision repair complex on chromatin by interacting 
with XPC and stimulating its recruitment to the DNA 
lesion, but DOT1L is not involved in transcriptional reg-
ulation of the DNA repair genes [7]. Therefore, in human 
melanoma DOT1L seems to behave as a tumor suppressor 
gene. In mESCs carrying a catalytically inactive G165R 
mutant, we also observed a protective role of DOT1L 
against UV radiation.
In our study, the R409H variant in DOT1L gene, which 
protects melanocytes from the UV-induced transition to 
melanoma, was identified upon WES of two members of a 
family with a family history of melanoma. The R409H was 
confirmed in other two affected family members, there-
fore co-segregating with melanoma in all four first-degree 
melanoma-affected family members. Then, we function-
ally explored this variant but we could neither detect his-
tone methyltransferase activity reduction in melanoma 
and mESCs nor an effect on UV-induced survival in 
mESCs. However, it is possible that dynamic changes in 
or alternative functions of H3K79me were missed in the 
assays used or that the role of R409 in melanocytes is not 
recapitulated in the cell model used here. Accordingly, 
two previously reported DOT1L variants (V135A and 
F243A) hardly showed a decrease of the DOT1L meth-
yltransferase activity [27]. R409 is located in a part of the 
DOT1L protein that is enriched for positively charged 
residues [28]. This region contains a nuclear localization 
signal [29] and is part of a C-terminal extension of the 
catalytic core of DOT1L that is required for nucleosome 
binding and DOT1L activity [28]. Furthermore, lysine 
410, adjacent to R409, was identified as a site that can be 
methylated by SUV39H1, suggesting that the function 
of this part of DOT1L may be subject to post-transla-
tional modifications. SUV39H1 targets RK sites [30], and 
the R409H mutation disrupts this RK motif. However, 
very little is known about the interactions between the 
DOT1L C-terminal extension and the nucleosome. 
Recent efforts to elucidate the mechanisms of these 
interactions by determining the structure of DOT1L 
bound to nucleosomes have not yet revealed the molecu-
lar details [31–33]. It has been reported that DOT1L only 
binds the ubiquitinated nucleosome, which is dependent 
on H2BK120 monoubiquitination and H2A-H2B acidic 
path, that subsequently enhances the catalytic func-
tion of the methyltransferase DOT1L [27]. However, 
the lack of unequivocal structural information is most 
likely caused by the dynamic nature of the interactions 
between the DOT1L C-terminal extension of the cata-
lytic core and the nucleosome. It could also be possible 
that the R409H mutation affects a methyltransferase-in-
dependent function of DOT1L. For example, budding 
yeast DOT1L functions as a transcription de-repressor, 
a histone chaperone and enhances H2B ubiquitination 
all independent of its methyltransferase activity [34–36]. 
However, in mammalian cells this activity of DOT1L has 
been shown to be required for several critical functions, 
including reactivation of repressed genes upon targeting, 
cycle progression in lung cancer cell lines, and leukaemic 
transformation in CALM-AF10 MLL-rearranged leu-
kemia [37–39]. Taken together, methyltransferase-inde-
pendent functions of DOT1L have been reported, but 
not in mammalian cells. Despite a lack of evidence for 
a direct functional effect of the R409H variant, several 
variants in DOT1L have been observed in independent 
familial and sporadic melanoma cases. Therefore, our 
finding reinforces the ones by Zhu et al. [7] and we con-
sider that is worthwhile to investigate the DOT1L vari-
ants in future WES and WGS studies involving large 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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familial melanoma cohorts, albeit that further functional 
and structural analyses are required in order to confirm 
DOT1L to be a melanoma-susceptibility gene.
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